A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

NCT07058519 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

250

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Osimertinib-based adaptive treatment
DRUG: Osimertinib 80 MG

Sponsor

Shanghai Chest Hospital

Collaborators

[object Object]